Biphenyl Wrinkled Mesoporous Silica Nanoparticles for pH-Responsive Doxorubicin Drug Delivery

Lin, Jason; Peng, Chuanqi; Ravi, Sanjana; Siddiki, A. K. M. Nur Alam; Zheng, Jie; Balkus, Kenneth J.

doi:10.3390/ma13081998

Cited by 22 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our research team is among the first to study KCC-1 for DDSs [42,43,68,69], and we think that research on KCC-1 will increase soon. In the literature, there are references to "spherical wrinkled mesoporous silica" (WMS) [70][71][72] and KCC-1 is known also "dendritic fibrous nano-silica" (DFNS) [73]. They were all obtained based on changing the synthesis conditions and parameters of the original synthesis method for KCC-1 particles.…”

Section: Discovery Synthesis and Properties Of Msnsmentioning

confidence: 99%

Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising Anticancer Strategy

AbouAitah

Łojkowski

2021

Pharmaceutics

View full text Add to dashboard Cite

Natural prodrugs derived from different natural origins (e.g., medicinal plants, microbes, animals) have a long history in traditional medicine. They exhibit a broad range of pharmacological activities, including anticancer effects in vitro and in vivo. They have potential as safe, cost-effective treatments with few side effects, but are lacking in solubility, bioavailability, specific targeting and have short half-lives. These are barriers to clinical application. Nanomedicine has the potential to offer solutions to circumvent these limitations and allow the use of natural pro-drugs in cancer therapy. Mesoporous silica nanoparticles (MSNs) of various morphology have attracted considerable attention in the search for targeted drug delivery systems. MSNs are characterized by chemical stability, easy synthesis and functionalization, large surface area, tunable pore sizes and volumes, good biocompatibility, controlled drug release under different conditions, and high drug-loading capacity, enabling multifunctional purposes. In vivo pre-clinical evaluations, a significant majority of results indicate the safety profile of MSNs if they are synthesized in an optimized way. Here, we present an overview of synthesis methods, possible surface functionalization, cellular uptake, biodistribution, toxicity, loading strategies, delivery designs with controlled release, and cancer targeting and discuss the future of anticancer nanotechnology-based natural prodrug delivery systems.

show abstract

Section: Discovery Synthesis and Properties Of Msnsmentioning

confidence: 99%

Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising Anticancer Strategy

AbouAitah

Łojkowski

2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In contrast, cells internalize nanoparticles, which involves a binding (adsorbing) process followed by the formation of vesicles, and then, the formed nanoparticle-containing vesicles are internalized by endocytosis [ 11 ]. It has been reported that a nanoparticle size of ~50 nm may result in higher tumor cell uptake and mesoporous silica nanoparticles ~50 nm in diameter had the highest loading in HeLa cells [ 57 , 58 ]. In our study, ~50 nm QD-SFNPs (~170 nm in wet state) showed the possibility of being internalized by EA.hy926 and HeLa cells ( Figure 9 , seen in the circle symbols).…”

Section: Discussionmentioning

confidence: 99%

The Interactions of Quantum Dot-Labeled Silk Fibroin Micro/Nanoparticles with Cells

et al. 2020

View full text Add to dashboard Cite

When silk fibroin particles are used for controlled drug delivery, particle size plays a key role in the location of the carrier on the cells as well as the transport pathway, utilization efficiency, and therapeutic effect of the drugs. In this study, the interactions of different-sized silk fibroin particles and cell lines were investigated. Silk fibroin microparticles with dry size of 1.9 ± 0.4 μm (2.7 ± 0.3 μm in wet state) and silk fibroin nanoparticles with dry size of 51.5 ± 11.0 nm (174.8 ± 12.5 nm in wet state) were prepared by salting-out method and high-voltage electrospray method, respectively. CdSe/ZnS quantum dots were coupled to the surface of the micro/nanoparticles. Photostability observations indicated that the fluorescence stability of the quantum dots was much higher than that of fluorescein isothiocyanate. In vitro, microparticles and nanoparticles were co-cultured with human umbilical vein endothelial cells EA.hy 926 and cervical cancer cells HeLa, respectively. The fluorescence test and cell viability showed that the EA.hy926 cells tended to be adhered to the microparticle surfaces and the cell proliferation was significantly promoted, while the nanoparticles were more likely to be internalized in HeLa cells and the cell proliferation was notably inhibited. Our findings might provide useful information concerning effective drug delivery that microparticles may be preferred if the drugs need to be delivered to normal cell surface, while nanoparticles may be preferred if the drugs need to be transmitted in tumor cells.

show abstract

“…Currently, chemotherapy drugs used for breast cancer include anthracyclines such as doxorubicin (DOX), 5,6 taxanes such as paclitaxel, 5,7 5‐fluorouracil (5‐FU), 8 cyclophosphamide (neosar, cytoxan), and carboplatin (paraplatin) 9 . In this regard, DOX is one of the most common drugs that possess low bioavailability due to poor solubility in water (the hydrophobic version of doxorubicin [doxorubicin free base]) 10–12 . Generally, DOX possesses cell‐cycle‐specific activities and not only leads to G0/S and G2/M arrest but also results in apoptosis due to the increases of oxygen radicals 13 .…”

Section: Introductionmentioning

confidence: 99%

Synthesis of doxorubicin‐loaded PBMA‐b‐POEGMA micelles and assessment of its anticancer activity against breast cancer cells (4T1)

Gharnas-ghamesh

Masoumi

Erfani‐Moghadam

2022

J of Applied Polymer Sci

View full text Add to dashboard Cite

Doxorubicin (DOX) is a chemotherapy drug that possesses many side effects. This study aimed to synthesize PBMA‐b‐POEGMA [poly (butyl methacrylate)‐b‐poly (oligo ethylene glycol methacrylate)] diblock copolymer as a nanocarrier for loading of DOX, promoting anticancer efficacy of the drug, and decreasing its side effects. Hence, PBMA‐b‐POEGMA diblock copolymer was first synthesized by the RAFT method and then DOX encapsulated into the micellar nanocarrier. Self‐assembly behavior of copolymers and physicochemical/biological properties of nanocarriers were assessed. DLS and TEM images showed nanocarriers possessed spherical‐uniform structure with the mean size and polydispersity of 27 ± 1.34 nm and 0.13 ± 0.21 for blank‐micelles as well as, 45 ± 2.32 nm and 0.18 ± 0.18 for DOX‐loaded micelles, respectively. Synthesized micelles also provided high drug encapsulation efficiency (>80%) with a drug loading content of 4.53%. Moreover, the maximum released amount of drug was reported at 69%, with the Korsmeyer‐Peppas model, as a more suitable model to describe the release behavior of DOX from nanocarriers. Biologically, block copolymers were biocompatible against COS‐7 and 4T1 cell lines, in addition, free‐DOX showed higher cytotoxicity than DOX‐loaded micelles. Furthermore, 0.5 μg/mL concentration of drug‐loaded micelle led to growth inhibition of more than 60% of cancerous cells, during 48 h, so that higher level of cellular uptake of drug and apoptosis in 4T1 cells was induced by drug‐loaded micelles.

show abstract

Biphenyl Wrinkled Mesoporous Silica Nanoparticles for pH-Responsive Doxorubicin Drug Delivery

Cited by 22 publications

References 37 publications

Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising Anticancer Strategy

Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising Anticancer Strategy

The Interactions of Quantum Dot-Labeled Silk Fibroin Micro/Nanoparticles with Cells

Synthesis of doxorubicin‐loaded PBMA‐b‐POEGMA micelles and assessment of its anticancer activity against breast cancer cells (4T1)

Contact Info

Product

Resources

About